Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1997-3-3
|
| pubmed:abstractText |
Susceptibility for type 1 autoimmune hepatitis has been associated with the major histocompatibility alleles DRB1*0301, DRB3*0101, DRB1*0401, and DRB4*0103, whereas the DRB1*1501 allele may protect from the disease. Our aim was to determine if these alleles or others influence clinical manifestations and prognosis. Eighty-six white patients were evaluated prospectively for immune features and outcomes. Class I alleles were determined by microlymphocytotoxicity, and class II alleles were assessed by polymerase chain reaction with sequence-specific oligonucleotide probes or sequence-specific primers. One hundred two white, normal subjects were typed in the same fashion. Patients with concurrent immunologic diseases were more commonly positive for DRB4*0103 than patients without these features (68% vs. 38%, P = .01). DRB1*0301 (86% vs. 45%, P = .008) and the DRB1*0301-DRB3*0101 haplotype (79% vs. 42%, P = .02) occurred more commonly in patients who deteriorated during corticosteroid therapy. In contrast, DRB1*0401 and the DRB1*0401-DRB4*0103 haplotype were associated with a lower frequency of death from liver failure or the need for transplantation than patients with other alleles (0% vs. 37%, P = .03). Patients with DRB1*0301 differed from those with DRB1*0401 in that they were younger and failed treatment more commonly (27% vs. 5%, P = .04). We conclude that alleles associated with susceptibility to type 1 autoimmune hepatitis also influence its clinical features and prognosis. DRB4*0103 is associated with concurrent immune diseases, DRB1*0301 with a poor treatment response, and DRB1*0401 with a lower frequency of hepatic death or transplantation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
317-23
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9021941-Adolescent,
pubmed-meshheading:9021941-Adrenal Cortex Hormones,
pubmed-meshheading:9021941-Adult,
pubmed-meshheading:9021941-Aged,
pubmed-meshheading:9021941-Alleles,
pubmed-meshheading:9021941-Antibodies, Antinuclear,
pubmed-meshheading:9021941-Autoimmune Diseases,
pubmed-meshheading:9021941-Disease Susceptibility,
pubmed-meshheading:9021941-Female,
pubmed-meshheading:9021941-Genes, MHC Class I,
pubmed-meshheading:9021941-Genes, MHC Class II,
pubmed-meshheading:9021941-HLA-DR Antigens,
pubmed-meshheading:9021941-Hepatitis,
pubmed-meshheading:9021941-Humans,
pubmed-meshheading:9021941-Male,
pubmed-meshheading:9021941-Middle Aged,
pubmed-meshheading:9021941-Muscle, Smooth,
pubmed-meshheading:9021941-Treatment Failure
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.
|
| pubmed:affiliation |
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
|
| pubmed:publicationType |
Journal Article
|